cause death from respiratory failure. In addition the paracetamol in combined preparations may cause death from hepatic failure, 4and in Britain, between 1970 and 1974, 28% of deaths from paracetamol poisoning were due to a dextropropoxyphene/paracetamol combination.8 The toxicity of dextropropoxyphene may also be enhanced by alcohol,6 7 10 and death has been reported from ingestion of only 15 tablets in combination with alcohol. 3 There is some evidence that dextropropoxyphene has addictive properties. 8 [10] [11] [12] [13] [14] Formal clinical trials suggest that it has low potency as an analgesic. Fifteen double-blind trials showed that codeine in lower or equal doses produced analgesia equal to or greater than dextropropoxyphene, and seven studies showed that aspirin and caffeine in various doses were of equal or greater efficacy.'5 In nine studies dextropropoxyphene was more effective than placebo but in another seven it was not.'5 A later study'6 found that it had less analgesic effect than aspirin or paracetamol alone. Despite this the combination of dextropropoxyphene and paracetamol remains extremely popular.
Australia is no exception to world trends, and "Digesic" (dextropropoxyphene hydrochloride 32-5 mg and paracetamol 325 mg, Dista) is one of the most widely prescribed analgesics.
For the reasons outlined above, on 1 March 1978 prescribing restrictions were introduced in our 517-bed teaching hospital. From that date combination products containing dextropropoxyphene could be prescribed only by consultants. We describe the results of these restrictions.
Methods
The pharmacy keeps records of numbers of tablets purchased in any given period. These figures were collected for the nine-month period before and after the introduction of restrictions for the following commonly prescribed analgesic tablets: dextropropoxyphene hydrochloride 32-5 mg/paracetamol 325 mg (Digesic); dextropropoxyphene napsylate 100 mg 65 mg hydrochloride (Doloxene); paracetamol soluble aspirin 300 mg; aspirin 300 mg/codeine 8 mg (Aspalgin); paracetamol 500 mg/codeine 8 mg (Panadeine); and aspirin 225 mg/paracetamol 150 mg/codeine 30 mg (Codral Forte). The actual numbers of tablets prescribed were not available, but note was made of the quantities of Digesic supplied to outpatients (90 000 patients a year) and inpatients (17 000 patients a year).
Results
The figure shows the numbers of tablets purchased before and after restrictions, and table I shows the individual tablets expressed as percentage of total analgesics purchased. Table II shows total outpatient and inpatient supplies of Digesic for the nine months before and after restrictions. The total number of analgesic tablets purchased over a nine-month period fell from 1-095 million to 0-774 million.
The use of Digesic in inpatients fell dramatically, but there was a slower decline in outpatient use. Prescribing of paracetamol increased by about half but that of soluble aspirin did not change. The use of compound analgesics, particularly Codral Forte, increased and since Codral Forte is very expensive the total cost of drugs fell proportionately less than the total number purchased-from A$13 375 to A$11 525 (table III) .
Some problems arose from using purchasing and supply figures to estimate drug usage. Tables II and III show that a total of 578 000 Digesic tablets were supplied before restrictions to outpatients and inpatients combined, but the total number of tablets purchased in the relevant period was 600 000. Similarly, after the restrictions 148 000 tablets were supplied to both outpatients and inpatients and yet only 65 000 were purchased. Thus a greater or lesser effect of the prescribing restriction could be deduced depending whether purchase data or supply data were used.
The purchasing figure for a further nine months from January to September 1979, during which restrictions persisted, were therefore examined (table III) . They showed that the total number of tablets had increased again from 774 000 to 854 000. Accompanying this was a rise in drug costs for analgesics, the new nine-month total being A$13 966. The reduction in amounts of Digesic and Doloxene purchased was largely balanced by increases in the amounts of paracetamol (Panadeine) and Codral Forte (table III) . 
Discussion
These results indicate that restricting the prescribing of a particular drug to consultants may have a substantial effect on prescribing patterns. The changes observed, however, raise important questions about the reasons for prescribing a particular drug, the wisdom of imposing restrictions, the importance of monitoring changes, and the methods of assessment to be used.
Our data are based on numbers of tablets purchased, since this is how our pharmacy does its auditing; and even had there been large stocks of Digesic at the time restrictions were imposed the figures for the third nine-month period we monitored suggest that there had been a true drop in the amount prescribed. Some outpatients, however, finding that they were not being given Digesic at the hospital, may have obtained prescriptions from their general practitioners.
Departments of pharmacy normally audit drug usage in terms of money spent and the acquisition of drugs. Inventory control centres on compliance with audit requirements rather than establishing an active record of the dispersement of drugs for ward units or doctors, and changes in drug usage cannot be identified quickly and accurately. We had not been fully aware of this difficulty before performing the present analysis.
Figures were available for the supply of Digesic to inpatient and outpatient departments. Inpatient prescribing of Digesic, predominately by junior staff, fell immediately. Of more interest is the lesser decline in outpatient, predominately consultant, prescribing. This suggests that some patients and experienced doctors believe that Digesic is a useful drug not readily substituted by any other product. Since the evidence for its analgesic properties is limited, its central effects may possibly be responsible for its popularity. Miller15 stated "it appears that factors other than intrinsic therapeutic value are responsible for the commercial success of propoxyphene." Digesic is marketed as an attractive, compact, oblong white tablet that is easily swallowed. In Australia, in 1978-9, prescriptions were written on pharmaceutical benefits for 2 346 840 tablets of Digesic. Prescribing numbers for another preparation (Capadex) with identical constituents but marketed as a green and yellow capsule were only 244 820. The popularity of Digesic may therefore be related to expert marketing techniques.
Our findings also indicate a definite tendency to prescribe compound analgesics. We were greatly concerned to see that a compound containing 30 mg of codeine phosphate (and pre-scribed two at a time) had become the compound analgesic of first choice. It is arguable that this could do more harm than the dextropropoxyphene it has replaced since codeine is well known to cause constipation, and this may be particularly dangerous in surgical wards. Of special concern is that this tendency to use the compound analgesics, in particular Codral Forte, became even more pronounced with longer follow-up.
We achieved our aim of reducing the use of Digesic within the hospital but created other problems. Our results show that prescribing restrictions are not the answer to the misuse and overuse of drugs. If they are introduced they should be carefully monitored by methods more subtle than the hospital pharmacy audit. At best they will only provide a short-term solution, and only by a continuous programme of active education of medical students and practising doctors will prescribing habits be improved.
